BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ramanujam VS, Anderson KE. Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias. Curr Protoc Hum Genet. 2015;86:17.20.1-17.20.26. [PMID: 26132003 DOI: 10.1002/0471142905.hg1720s86] [Cited by in Crossref: 47] [Cited by in F6Publishing: 55] [Article Influence: 5.9] [Reference Citation Analysis]
Number Citing Articles
1 Sreevalsakumar S, Nair C, Vellingiri B, Valsala Gopalakrishnan A. Porphyria. Genetic Syndromes 2023. [DOI: 10.1007/978-3-319-66816-1_1784-1] [Reference Citation Analysis]
2 Ma CD, Bonkovsky HL. Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias. Mol Genet Metab Rep 2022;33:100915. [PMID: 36105850 DOI: 10.1016/j.ymgmr.2022.100915] [Reference Citation Analysis]
3 Vachiravit Sriprakoon, Chalisa Ittagornpunth, Nakorn Puapaiboon, Aekasit Bunyahathaipat, Punnapat Piriyanon, Sookkasem Khositseth, Kitiwan Rojnueangnit. Acute Intermittent Porphyria: Complete Phenotype in a Patient with p.Arg173Trp Variant in Thailand. Am J Case Rep 2022;23. [PMID: 36329616 DOI: 10.12659/AJCR.937695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Moshayedi A, Mochel MC, Brooks AN, Laver J, Salkey KS. A 9-year-old girl with blisters on the hands and face: An early presentation of variegate porphyria. Pediatr Dermatol 2022. [PMID: 36178265 DOI: 10.1111/pde.15150] [Reference Citation Analysis]
5 Ventura P, Sardh E, Longo N, Balwani M, Plutzky J, Gouya L, Phillips J, Rhyee S, Fanelli MJ, Sweetser MT, Petrides PE. Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran. Expert Rev Gastroenterol Hepatol 2022. [PMID: 35929959 DOI: 10.1080/17474124.2022.2110469] [Reference Citation Analysis]
6 Lynch J, Wang Y, Li Y, Kavdia K, Fukuda Y, Ranjit S, Robinson CG, Grace CR, Xia Y, Peng J, Schuetz JD. PPIX-binding Proteins Reveal Porphyrin Synthesis and Ferroptosis Link.. [DOI: 10.1101/2022.06.01.494336] [Reference Citation Analysis]
7 Francesca G, Nicolli A, Colaiocco A, Di Pierro E, Graziadei G. Psychological Aspect and Quality of Life in Porphyrias: A Review. Diagnostics 2022;12:1193. [DOI: 10.3390/diagnostics12051193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Marcacci M, Ricci A, Cuoghi C, Marchini S, Pietrangelo A, Ventura P. Challenges in diagnosis and management of acute hepatic porphyrias: from an uncommon pediatric onset to innovative treatments and perspectives. Orphanet J Rare Dis 2022;17:160. [PMID: 35392955 DOI: 10.1186/s13023-022-02314-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Sirch C, Khanna N, Frassetto L, Bianco F, Artero ML. Diagnosis of acute intermittent porphyria in a renal transplant patient: A case report. World J Transplant 2022; 12(1): 8-14 [DOI: 10.5500/wjt.v12.i1.8] [Reference Citation Analysis]
10 Sernicola A, Cama E, Pelizzo MG, Tessarolo E, Nicolli A, Viero G, Alaibac M. In vitro Assessment of Solar Filters for Erythropoietic Protoporphyria in the Action Spectrum of Protoporphyrin IX. Front Med (Lausanne) 2021;8:796884. [PMID: 34988101 DOI: 10.3389/fmed.2021.796884] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zakir F, Mohapatra S, Farooq U, Mirza MA, Iqbal Z. Introduction to metabolic disorders. Drug Delivery Systems for Metabolic Disorders 2022. [DOI: 10.1016/b978-0-323-99616-7.00001-3] [Reference Citation Analysis]
12 Basetty V, Deruiter J, Pathak S, Dua K, Dhanasekaran M. Advanced drug delivery systems targeting to improve therapeutic outcomes in porphyria. Drug Delivery Systems for Metabolic Disorders 2022. [DOI: 10.1016/b978-0-323-99616-7.00022-0] [Reference Citation Analysis]
13 Ventura P, Bonkovsky HL, Gouya L, Aguilera-Peiró P, Montgomery Bissell D, Stein PE, Balwani M, Anderson DKE, Parker C, Kuter DJ, Monroy S, Oh J, Ritchie B, Ko JJ, Hua Z, Sweetser MT, Sardh E; ENVISION Investigators. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study. Liver Int 2022;42:161-72. [PMID: 34717041 DOI: 10.1111/liv.15090] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
14 Tekin S, Karagülmez AM, Erdoğan Ç, Değirmenci E, Tokgün O. Diagnostic difficulty in a patient with recurrent attacks of acute polyneuropathy: Acute intermittent porphyria. Cukurova Medical Journal 2021;46:1719-1724. [DOI: 10.17826/cumj.982619] [Reference Citation Analysis]
15 Anderson KE, Desnick RJ, Stewart MF, Ventura P, Bonkovsky HL. Acute Hepatic Porphyrias: "Purple Flags"-Clinical Features that should Prompt Specific Diagnostic Testing. Am J Med Sci 2021:S0002-9629(21)00337-2. [PMID: 34606756 DOI: 10.1016/j.amjms.2021.09.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Gilles A, Vermeersch S, Vermeersch P, Wolff F, Cotton F, Tilleux S, Cassiman D. Expert consensus statement on acute hepatic porphyria in Belgium. Acta Clin Belg 2021;:1-7. [PMID: 34369323 DOI: 10.1080/17843286.2021.1961056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Pająk R, Mendela E, Będkowska N, Paprocka J. Update on Neuropathies in Inborn Errors of Metabolism. Brain Sci 2021;11:763. [PMID: 34201281 DOI: 10.3390/brainsci11060763] [Reference Citation Analysis]
18 Chen X, Jiang F, Liang H, Peng H, Chen Y, Luo H. A familial case of basophilic stippling cells in lead poisoning. Int J Lab Hematol 2021. [PMID: 34075716 DOI: 10.1111/ijlh.13614] [Reference Citation Analysis]
19 Huang S, Li R, Yuan Y. Severe neuropathic attack in a woman with acute intermittent porphyria: a case report. J Int Med Res 2021;49:300060520983143. [PMID: 33430675 DOI: 10.1177/0300060520983143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Gill L, Burrell S, Chamberlayne J, Lombardelli S, Mora J, Mason N, Schurer M, Merkel M, Meninger S, Ko JJ. Patient and caregiver experiences of living with acute hepatic porphyria in the UK: a mixed-methods study. Orphanet J Rare Dis 2021;16:187. [PMID: 33902669 DOI: 10.1186/s13023-021-01816-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Sachau J, Kersebaum D, Baron R, Dickenson AH. Unusual Pain Disorders - What Can Be Learned from Them? J Pain Res 2020;13:3539-54. [PMID: 33758536 DOI: 10.2147/JPR.S287603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Kurkina NV, Skvortsov VV, Polozova EI, Vyshinskaya VA. Acute intermittent porphyria: familial disease cases (clinical observation). Spravočnik vrača obŝej praktiki (Journal of Family Medicine) 2021. [DOI: 10.33920/med-10-2102-04] [Reference Citation Analysis]
23 Safi R, Malek E, Nemer G, Sayed R, Eid E, Khalil S, Nasser N, Abbas O, Mohsen-Kanson T, Kurban M. Comparative characterization of sun exposed and sun protected skin-derived mesenchymal-like stem cells in variegate porphyria and healthy individuals. Photodermatol Photoimmunol Photomed 2021;37:202-13. [PMID: 33259115 DOI: 10.1111/phpp.12635] [Reference Citation Analysis]
24 Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res 2021;149:1-61. [PMID: 33579421 DOI: 10.1016/bs.acr.2020.10.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
25 Knotek M, Novak R, Jaklin-Kelez A, Mrzljak A. Combined liver-kidney transplantation for rare diseases. World J Hepatol 2020; 12(10): 722-737 [PMID: 33200012 DOI: 10.4254/wjh.v12.i10.722] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Massachi S, Epstein J, Hurd J, Bonkovsky HL. Cost savings with hemin versus givosiran for the treatment of patients with acute intermittent porphyria (AIP). J Med Econ 2020;23:1441-9. [PMID: 33043761 DOI: 10.1080/13696998.2020.1835306] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Elsaid MI, Li Y, Catalano C, Minacapelli CD, Gupta K, Rustgi VK. Healthcare Utilization and Cost Burden of Porphyria in Commercially Insured Adults in the United States. Pharmacoecon Open 2021;5:89-100. [PMID: 32897528 DOI: 10.1007/s41669-020-00229-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Nevins EG, Wijesiriwardana A. Erythropoietic protoporphyria in pregnancy. J Obstet Gynaecol 2021;41:657-8. [PMID: 32715814 DOI: 10.1080/01443615.2020.1777954] [Reference Citation Analysis]
29 Gouya L, Ventura P, Balwani M, Bissell DM, Rees DC, Stölzel U, Phillips JD, Kauppinen R, Langendonk JG, Desnick RJ, Deybach JC, Bonkovsky HL, Parker C, Naik H, Badminton M, Stein PE, Minder E, Windyga J, Bruha R, Cappellini MD, Sardh E, Harper P, Sandberg S, Aarsand AK, Andersen J, Alegre F, Ivanova A, Talbi N, Chan A, Querbes W, Ko J, Penz C, Liu S, Lin T, Simon A, Anderson KE. EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks. Hepatology 2020;71:1546-58. [PMID: 31512765 DOI: 10.1002/hep.30936] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 20.7] [Reference Citation Analysis]
30 Ferranti EP, Frediani JK, Mitchell R, Fernandes J, Li S, Jones DP, Corwin E, Dunlop AL. Early Pregnancy Serum Metabolite Profiles Associated with Hypertensive Disorders of Pregnancy in African American Women: A Pilot Study. J Pregnancy 2020;2020:1515321. [PMID: 32148965 DOI: 10.1155/2020/1515321] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
31 Khalil S, Eid E, Hamieh L, Bardawil T, Moujaes Z, Khalil W, Abbas O, Kurban M. Genodermatoses with teeth abnormalities. Oral Dis 2020;26:1032-44. [PMID: 32027427 DOI: 10.1111/odi.13295] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
32 Al‐hage J, Nemer G, Kassabian P, Kurban M. Unusual presentation of severe photosensitivity and neurodevelopmental delay in a consanguineous family. Clin Exp Dermatol 2020;45:117-119. [DOI: 10.1111/ced.13948] [Reference Citation Analysis]
33 de Paula Brandão PR, Titze-de-almeida SS, Titze-de-almeida R. Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran. Mol Diagn Ther 2020;24:61-8. [DOI: 10.1007/s40291-019-00438-6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 11.5] [Reference Citation Analysis]
34 Pshenichnikova OS, Goncharova MV, Pustovoit YS, Karpova IV, Surin VL. PILOT RESEARCH OF A GENETIC PREDISPOSITION FOR CLINICAL MANIFESTATIONS OF ACUTE INTERMITTENT PORPHYRIA. Gematologiâ i transfuziologiâ 2019;64:123-137. [DOI: 10.35754/0234-5730-2019-64-2-123-137] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Abenavoli L, Dastoli S, Bennardo L, Boccuto L, Passante M, Silvestri M, Proietti I, Potenza C, Luzza F, Nisticò SP. The Skin in Celiac Disease Patients: The Other Side of the Coin. Medicina (Kaunas) 2019;55:E578. [PMID: 31505858 DOI: 10.3390/medicina55090578] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
36 Ferreira GC, Oberstaller J, Fonseca R, Keller TE, Adapa SR, Gibbons J, Wang C, Liu X, Li C, Pham M, Dayhoff Ii GW, Duong LM, Reyes LT, Laratelli LE, Franz D, Fatumo S, Bari AG, Freischel A, Fiedler L, Dokur O, Sharma K, Cragun D, Busby B, Jiang RHY. Iron Hack - A symposium/hackathon focused on porphyrias, Friedreich's ataxia, and other rare iron-related diseases. F1000Res 2019;8:1135. [PMID: 31824661 DOI: 10.12688/f1000research.19140.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
37 Li Y, Yu N, Han D, Ding Y, Xu Y. A first report of porphyria cutanea tarda successfully treated with glycyrrhizin. Dermatol Ther 2019;32:e13014. [PMID: 31269308 DOI: 10.1111/dth.13014] [Reference Citation Analysis]
38 Maitra D, Bragazzi Cunha J, Elenbaas JS, Bonkovsky HL, Shavit JA, Omary MB. Porphyrin-Induced Protein Oxidation and Aggregation as a Mechanism of Porphyria-Associated Cell Injury. Cell Mol Gastroenterol Hepatol 2019;8:535-48. [PMID: 31233899 DOI: 10.1016/j.jcmgh.2019.06.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
39 Maitra D, Carter EL, Richardson R, Rittié L, Basrur V, Zhang H, Nesvizhskii AI, Osawa Y, Wolf MW, Ragsdale SW, Lehnert N, Herrmann H, Omary MB. Oxygen and Conformation Dependent Protein Oxidation and Aggregation by Porphyrins in Hepatocytes and Light-Exposed Cells. Cell Mol Gastroenterol Hepatol 2019;8:659-682.e1. [PMID: 31173894 DOI: 10.1016/j.jcmgh.2019.05.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
40 Poh-fitzpatrick MB. Photocutaneous Porphyrias. Curr Derm Rep 2019;8:52-62. [DOI: 10.1007/s13671-019-0253-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Kakoullis L, Louppides S, Papachristodoulou E, Panos G. Porphyrias and photosensitivity: pathophysiology for the clinician. Postgrad Med 2018;130:673-86. [PMID: 30296862 DOI: 10.1080/00325481.2018.1533380] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
42 Chiabrando D, Fiorito V, Petrillo S, Tolosano E. Unraveling the Role of Heme in Neurodegeneration. Front Neurosci 2018;12:712. [PMID: 30356807 DOI: 10.3389/fnins.2018.00712] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
43 Nguyen LH, Khamisa K. Porphyria cutanea tarda presenting as milia and blisters. CMAJ 2018;190:E623. [PMID: 29789288 DOI: 10.1503/cmaj.180152] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
44 Duque-serrano L, Patarroyo-rodriguez L, Gotlib D, Molano-eslava JC. Psychiatric Aspects of Acute Porphyria: a Comprehensive Review. Curr Psychiatry Rep 2018;20. [DOI: 10.1007/s11920-018-0867-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
45 Frank J. Porphyrien. Braun-Falco's Dermatologie, Venerologie und Allergologie 2018. [DOI: 10.1007/978-3-662-49546-9_94-1] [Reference Citation Analysis]
46 Frank J. Porphyrien. Braun-Falco’s Dermatologie, Venerologie und Allergologie 2018. [DOI: 10.1007/978-3-662-49544-5_94] [Reference Citation Analysis]
47 Al-harazi AA, Al-eryani BM, Al-sharafi BA. Neonatal hemolytic anemia does not always indicate thalassemia: a case report. BMC Res Notes 2017;10:476. [DOI: 10.1186/s13104-017-2803-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
48 Kumar S, Bhalla A, Sharma N, Dhibar DP, Kumari S, Varma S. Clinical, Biochemical Characteristics and Hospital Outcome of Acute Intermittent Porphyria Patients: A Descriptive Study from North India. Ann Indian Acad Neurol 2017;20:263-9. [PMID: 28904459 DOI: 10.4103/aian.AIAN_91_17] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
49 Arora S, Young S, Kodali S, Singal AK. Hepatic porphyria: A narrative review. Indian J Gastroenterol 2016;35:405-18. [PMID: 27796941 DOI: 10.1007/s12664-016-0698-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
50 D’avola D, Gonzalez Aseguinolaza G. Prospect and progress of gene therapy in acute intermittent porphyria. Expert Opinion on Orphan Drugs 2016;4:711-7. [DOI: 10.1080/21678707.2016.1191346] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]